Scientific Advisory Board

Joseph A. Leveque


Joseph A. Leveque, M.D is the President and Chief Executive Officer at Medikine, a biotechnology company pioneering peptide mimesis to harness the therapeutic potential of T cell stemness for the treatment of cancer and as an adjunct for use in adoptive cell therapy, vaccines, and for addressing potential complications of aging-related immunosenescence. Prior to Medikine, Dr. Leveque was the Chief Medical Officer (CMO) at Mirati Therapeutics focused on the development of KRAS inhibitors for the treatment of lung, colorectal, and pancreatic cancers. Dr. Leveque obtained a bachelor’s degree in biology with a minor in mathematics from Santa Clara University, an MBA from The Wharton School at the University of Pennsylvania and a M.D. from the University of Texas Medical School. He completed his internship and residency in internal medicine at the UCLA Cedars-Sinai Medical Center. In 2012 Dr. Leveque was recognized by the Multiple Myeloma Research Foundation as a Top 10 innovator in the field of multiple myeloma.

Arrow Shape Facebook Instagram Twitter Youtube Play Arrow Left